These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 28079010)

  • 1. Discovery of Natural Proteasome Inhibitors as Novel Anticancer Therapeutics: Current Status and Perspectives.
    Wang H; Yang Q; Dou QP; Yang H
    Curr Protein Pept Sci; 2018 Feb; 19(4):358-367. PubMed ID: 28079010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic potential of microbial proteasome inhibitors.
    Momose I; Kawada M
    Int Immunopharmacol; 2016 Aug; 37():23-30. PubMed ID: 26589840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A High-Content Screening Assay for the Discovery of Novel Proteasome Inhibitors from Formosan Soft Corals.
    Ling XH; Wang SK; Huang YH; Huang MJ; Duh CY
    Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30347865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Search for Inhibitors of the Ubiquitin-Proteasome System from Natural Sources for Cancer Therapy.
    Tsukamoto S
    Chem Pharm Bull (Tokyo); 2016; 64(2):112-8. PubMed ID: 26833439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and development of second-generation proteasome inhibitors.
    Kirk CJ
    Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clogging the Ubiquitin-Proteasome Machinery with Marine Natural Products: Last Decade Update.
    Della Sala G; Agriesti F; Mazzoccoli C; Tataranni T; Costantino V; Piccoli C
    Mar Drugs; 2018 Nov; 16(12):. PubMed ID: 30486251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marizomib, a potent second generation proteasome inhibitor from natural origin.
    Ma L; Diao A
    Anticancer Agents Med Chem; 2015; 15(3):298-306. PubMed ID: 25403165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the proteasome pathway.
    Tsukamoto S; Yokosawa H
    Expert Opin Ther Targets; 2009 May; 13(5):605-21. PubMed ID: 19397479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of proteasome inhibitors as research tools and cancer drugs.
    Goldberg AL
    J Cell Biol; 2012 Nov; 199(4):583-8. PubMed ID: 23148232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the ubiquitin+proteasome system in solid tumors.
    Driscoll JJ; Woodle ES
    Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubiquitin-proteasome system as a target for anticancer treatment-an update.
    Kim YJ; Lee Y; Shin H; Hwang S; Park J; Song EJ
    Arch Pharm Res; 2023 Jul; 46(7):573-597. PubMed ID: 37541992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
    Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
    Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
    Zhang W; Wang X; Zhang H; Wen T; Yang L; Miao H; Wang J; Liu H; Yang X; Lei M; Zhu Y
    Bioorg Med Chem; 2021 Jun; 40():116182. PubMed ID: 33971487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
    Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP
    Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-based screening of extracts of natural sources to search for inhibitors of the ubiquitin-proteasome system and identification of proteasome inhibitors from the fungus Remotididymella sp.
    Nishimura S; Hitora Y; Kawahara T; Tanabe M; Ogata E; Kato H; Srikoon P; Watanabe T; Tsukamoto S
    Bioorg Med Chem Lett; 2022 Mar; 59():128566. PubMed ID: 35063633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel 20S proteasome inhibitors by rational topology-based scaffold hopping of bortezomib.
    Xu Y; Yang X; Chen Y; Chen H; Sun H; Li W; Xie Q; Yu L; Shao L
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2148-2152. PubMed ID: 29773504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, and Biological Activity of Isosyringolin A.
    Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
    Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibitors for multiple myeloma.
    Okazuka K; Ishida T
    Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
    Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
    Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
    Ri M
    Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.